Navigation Links
CellCyte Genetics Signs Collaborative Agreement With Northwestern University's Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCyte's CCG-TH30 Product Candidate
Date:5/28/2008

BOTHELL, Wash., May 28 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG) has entered into a collaborative research agreement with Northwestern University's Feinberg School of Medicine to perform an acute myocardial infarction (AMI) disease model study in mice using CellCyte's CCG-TH30 product candidate. The goal of the study is to evaluate the functional benefit of the CCG-TH30 therapy in a disease model outcome study representative of the AMI (heart attack) indication. Douglas W. Losordo, M.D., a leader in cardiovascular cell therapy research and Director of Feinberg Cardiovascular Research Institute, will serve as the principal investigator on the study.

"We are extremely pleased to collaborate with Dr. Losordo, as he is one of the preeminent leaders in cardiovascular regenerative medicine," said Ronald W. Berninger, Ph.D., CellCyte's Chief Scientific Officer. "This is another important collaboration for our program, as it allows us to evaluate the functional outcome benefit of the CCG-TH30 therapy as compared to standard cell therapies where delivery agents aren't used."

About Douglas W. Losordo, M.D.

Dr. Losordo is a cardiologist at Northwestern Memorial Hospital and is the Director of Cardiovascular Regenerative Medicine and the Feinberg Cardiovascular Research Institute, both at Northwestern Memorial Hospital. He is board certified in Cardiovascular Disease, Internal Medicine, and Interventional Cardiology. Dr. Losordo is a member of the Northwestern Memorial Faculty Foundation, and his clinical interests include gene therapy, stem cell transplant, regenerative medicine and angiogenesis. He has preclinical expertise in animal models of cardiac disease, as well as preclinical and clinical expertise in stem cell therapy for cardiac regeneration. In recognition of his continued and outstanding achievements, Northwestern University's Feinberg School of Medicine named Dr. Losordo the Eileen M.
'/>"/>

SOURCE CellCyte Genetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
2. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
3. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
4. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
5. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
6. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
7. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
8. Genetics Determine Optimal Drug Dose of Common Anticoagulant
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Newswire/-- FromNovember16-18,Phonak,theleadingman...secondeditionoftheHearingCareforAdultsConference,f...nferencebroughttogetherleadingexpertsinagingandaud...oworkeverydaywitholderpeoplewithhearinglossforanop...archandtrendsinhearingcareforolderpeople. ,, W...
(Date:11/25/2009)...FirstCall/--FormanyofthemillionsofhearingimpairedA... hearingloss ,theholidaysmaynotbeallthathappy,says...esidentofHearUSA(Amex: EAR ),oneofAmerica,slargest...velinkedhearinglosstostress,frustration,andsociali...eringswithfamiliesandfriends,whenmanyofthosewithhe...
(Date:11/25/2009)...-RegadoBiosciences,aprivatelyheldcompanyleadingthe...olagents,announcedthatDavidMazzo,PhD,CEOandPreside...thCareConferenceattheNewYorkPalaceHotelinNewYorkCi...nTuesday,December1andwillincludeanoverviewoftheCom...ram,theanticoagulantsystem,REG1.Thehealthcareindus...
Breaking Medicine Technology:Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Right to Health Care Debated at New ProCon org Website 58181 1Right to Health Care Debated at New ProCon org Website 58181 2Spherix Incorporated Announces Annual Shareholders Meeting Date 14241 1Spherix Incorporated Announces Annual Shareholders Meeting Date 14241 2Spherix Incorporated Announces Annual Shareholders Meeting Date 14241 3Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 1Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 2Pre clinical Data Show OrbusNeichs Combo Bio engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 5039 3
..., Dec. 1 Roche announced today that a,comparative...ved pain and,discomfort associated with blood gluc...ing systems and lancing devices were deemed least ...the ACCU-CHEK Aviva and ACCU-CHEK Compact,Plus blo...lticlix, ACCU-CHEK,Softclix and ACCU-CHEK Softclix...
...TING, Pa., Dec. 1 Genaera Corporation (Nasdaq: ...s begun in study MSI-1436C-102 (Study 102), the mu...ine (MSI-1436) in overweight and obese type 2 diab...atment of type 2 diabetes and obesity which works ... leptin pathways through the highly selective inhi...
Other Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3
(Date:11/25/2009)...re/--TheBartleHallConventionCenterwilltemporarilyb...nKansasCityhoststhelatestinaseriesofmassivefreecli...hasthepotentialtobethebiggestoneyet,becauseitwille...sinsteadofoveraweekend,"SheriWood,executivedirecto...ationalAssociationofFreeClinics(NAFC). ,, Atpre...
(Date:11/25/2009)...wire-USNewswire/--AnarticlebyJanetWoodcock,M.D.,di...,titled"ADifficultBalance-PainManagement,DrugSafet...nglandJournalofMedicine. ,, (Logo: http://www.n...nthearticle,WoodcockdiscussesFDAeffortstostrikeaba...tandmanagingtherisksposedbyvariousanalgesics.Asexa...
(Date:11/25/2009)... statistically significant survival benefit from a...ceptor (ER)-positive tumors had high levels of pho...S118-P), according to a brief communication publis...onal Cancer Institute . , Approximately 50% of b...inical studies have shown that ER-alpha S118-P is ...
(Date:11/25/2009)...nd treatment clinics to resume Monday, Nov. 30 , ... 25, 2009 -- Centegra Health System is continuing ...s at four Centegra Primary Care (CPC) vaccination ...ved. The clinics are at CPC sites in Huntley, Wood...s follows: ,   From 4:30 to 7:30 p.m. ...
(Date:11/25/2009)...e-USNewswire/--TheAmericanAssociationforHomecareen...28,whichisdesignedtosubstantiallyimprovetoolsandre...sintroducedbySen.GeorgeLeMieux(R-Fla.). ,, TheL...ciationforHomecareoutlinedinits13-pointanti-frauda...ebruary.Thoseprovisionsincludecallingforreal-timea...
Breaking Medicine News(10 mins):Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...red weeks earlier than a decade ago and is likely ...aid . "Despite uncertainties in the magnit...ry, one consistent feature of extant and projected...ute, University of Aarhus, Denmark in the June 19 ...
...ess Margaret Hospital (PMH) are using a new way to...ive radiation therapy , takes less than an hour an...ents. The PMH team combined the expertise of ...irst time the portable intrabeam radiotherapy mach...
... one parent smoking have five times as much cotini...nts whose parents are non-smokers , according to a...ase in Childhood. The study was led by res...ts) and found that having a mother who smoked quad...
...rt is well known. But what is not is that even dur...nges. While diabetes could lead to blindness, limb...w Australian study says that people displaying mer.... Researchers at the International Diabete...
...view of previous studies indicates that two doses ...rovides substantial benefit to HIV-negative women ...ecessary for HIV-positive women. In malaria-e...alaria during their first and second pregnancies, ...
...endered jobless under the new recruitment process ... hardest hit . The new system will undermi...ce. Non-urgent patient care in England could be hi...idelio Group of senior doctors. The group is tryin...
Other Medicine News:Health News:Interoperative Radiotherapy for Breast Cancer Patients 2Health News:Smokers Blow Their Infants Health into Thin Air 2Health News:Even Pre-diabetes can Kill, Australian Study Says 2Health News:Effective Treatment for Malaria Control 2Health News:Effective Treatment for Malaria Control 3Health News:The New Recruitment Process Leaves Thousands of Doctors Jobless 2
Columbus Total Knee System
Shandon Humidity Chamber
Shandon Mini Hotplate
Shandon Histobath 2
Medicine Products: